Moderna Inc MRNA shares are trading higher by 3.2% at $174.69 Wednesday afternoon on continued strength after the company on Tuesday announced that the Phase 2/3 study of its COVID-19 vaccine in adolescents met its primary immunogenicity endpoint.
Moderna is commercial-stage biotech that was founded in 2010. The firm's mRNA technology was rapidly validated with its COVID-19 vaccine, which was authorized in the United States in December 2020. Moderna had 24 mRNA development programs as of early 2021, with 13 of these in clinical trials. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
